Cargando…

Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study

AIM: The aim of our study was to evaluate the potential role of resistin in estimating the 30 days prognosis in patients with hypoxic-ischemic organ injury who survived after a cardiac arrest (CA). MATERIALS AND METHODS: The study included 40 patients resuscitated after a non-traumatic out-of-hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tat, Raluca Mihaela, Golea, Adela, Vesa, Ştefan Cristian, Ionescu, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334922/
https://www.ncbi.nlm.nih.gov/pubmed/30650128
http://dx.doi.org/10.1371/journal.pone.0210666
_version_ 1783387810368061440
author Tat, Raluca Mihaela
Golea, Adela
Vesa, Ştefan Cristian
Ionescu, Daniela
author_facet Tat, Raluca Mihaela
Golea, Adela
Vesa, Ştefan Cristian
Ionescu, Daniela
author_sort Tat, Raluca Mihaela
collection PubMed
description AIM: The aim of our study was to evaluate the potential role of resistin in estimating the 30 days prognosis in patients with hypoxic-ischemic organ injury who survived after a cardiac arrest (CA). MATERIALS AND METHODS: The study included 40 patients resuscitated after a non-traumatic out-of-hospital CA admitted in Emergency Department (ED). All patients were followed for 30 days after CA or until death. Clinical data on admission were recorded. Blood samples were collected on admission in ED (0-time interval), and at 6, 12, 24, 48- and 72-hours following resuscitation. Serum concentrations of resistin, S100B and neuron specific enolase (NSE) were measured. Several predictive scores for the mortality at 30 days were created with logistic regressions. RESULTS: At each time interval, median serum levels of resistin and S100 B were significantly higher in non-survivors compared to survivors. For NSE, plasma levels were significantly lower in survivors as compared to non-survivors at 48 and 72 hours, respectively. Accurate predictive scores for 30-days mortality were the ones which included the values of resistin and S100B measured at 12 hours after admittance [AUC 0.938 (0.813–0.989), sensitivity 85.71% (67.3%– 96%), specificity 91.67% (61.5%’99.8%), p<0.001], which included the values of all three markers measured at 12 hours after admittance [AUC 0.955 (0.839–0.995), sensitivity 82.14% (63.1%’93.9%), specificity 100.00% (73.5%’100.0%), p<0.001] and the that included the values of resistin and S-100B at 6 hours together with serum lactate on admission [AUC = 0.994 (0.901–1.0), sensitivity 96.4% (81.7%’99.9%), specificity 100.00% (73.5%’100.0%), p<0.001]. CONCLUSION: In our study, serum levels of resistin or a combination of resistin with S-100B or resistin with S-100B and lactate, were highly predictive for 30 days mortality in resuscitated patients after CA. Further studies on large number of patients are needed to confirm our data.
format Online
Article
Text
id pubmed-6334922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63349222019-01-31 Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study Tat, Raluca Mihaela Golea, Adela Vesa, Ştefan Cristian Ionescu, Daniela PLoS One Research Article AIM: The aim of our study was to evaluate the potential role of resistin in estimating the 30 days prognosis in patients with hypoxic-ischemic organ injury who survived after a cardiac arrest (CA). MATERIALS AND METHODS: The study included 40 patients resuscitated after a non-traumatic out-of-hospital CA admitted in Emergency Department (ED). All patients were followed for 30 days after CA or until death. Clinical data on admission were recorded. Blood samples were collected on admission in ED (0-time interval), and at 6, 12, 24, 48- and 72-hours following resuscitation. Serum concentrations of resistin, S100B and neuron specific enolase (NSE) were measured. Several predictive scores for the mortality at 30 days were created with logistic regressions. RESULTS: At each time interval, median serum levels of resistin and S100 B were significantly higher in non-survivors compared to survivors. For NSE, plasma levels were significantly lower in survivors as compared to non-survivors at 48 and 72 hours, respectively. Accurate predictive scores for 30-days mortality were the ones which included the values of resistin and S100B measured at 12 hours after admittance [AUC 0.938 (0.813–0.989), sensitivity 85.71% (67.3%– 96%), specificity 91.67% (61.5%’99.8%), p<0.001], which included the values of all three markers measured at 12 hours after admittance [AUC 0.955 (0.839–0.995), sensitivity 82.14% (63.1%’93.9%), specificity 100.00% (73.5%’100.0%), p<0.001] and the that included the values of resistin and S-100B at 6 hours together with serum lactate on admission [AUC = 0.994 (0.901–1.0), sensitivity 96.4% (81.7%’99.9%), specificity 100.00% (73.5%’100.0%), p<0.001]. CONCLUSION: In our study, serum levels of resistin or a combination of resistin with S-100B or resistin with S-100B and lactate, were highly predictive for 30 days mortality in resuscitated patients after CA. Further studies on large number of patients are needed to confirm our data. Public Library of Science 2019-01-16 /pmc/articles/PMC6334922/ /pubmed/30650128 http://dx.doi.org/10.1371/journal.pone.0210666 Text en © 2019 Tat et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tat, Raluca Mihaela
Golea, Adela
Vesa, Ştefan Cristian
Ionescu, Daniela
Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title_full Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title_fullStr Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title_full_unstemmed Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title_short Resistin—Can it be a new early marker for prognosis in patients who survive after a cardiac arrest? A pilot study
title_sort resistin—can it be a new early marker for prognosis in patients who survive after a cardiac arrest? a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334922/
https://www.ncbi.nlm.nih.gov/pubmed/30650128
http://dx.doi.org/10.1371/journal.pone.0210666
work_keys_str_mv AT tatralucamihaela resistincanitbeanewearlymarkerforprognosisinpatientswhosurviveafteracardiacarrestapilotstudy
AT goleaadela resistincanitbeanewearlymarkerforprognosisinpatientswhosurviveafteracardiacarrestapilotstudy
AT vesastefancristian resistincanitbeanewearlymarkerforprognosisinpatientswhosurviveafteracardiacarrestapilotstudy
AT ionescudaniela resistincanitbeanewearlymarkerforprognosisinpatientswhosurviveafteracardiacarrestapilotstudy